Supplementary Online Content

Gencer B, Mach F, Murphy SA, et al. Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial. *JAMA Cardiol*. Published online May 20, 2020. doi:10.1001/jamacardio.2020.0882

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. CONSORT diagram



eTable 1. Baseline characteristics of patients with recent vs remote MI in FOURIER

Characteristics	Recent MI (≤12 months) N=5711	Remote MI (>12 months) N=16 609	P Value
Demographics			
Age, mean (SD), y	59.6 (9.2)	63.1 (8.8)	< 0.001
Male sex, %	4442 (77.8)	13074 (78.7)	0.14
White race, %	4870 (85.3)	14322 (86.2)	0.073
Mean weight, mean (SD), kg	83.9 (16.5)	86.4 (17.3)	< 0.001
Region, %			< 0.001
North America	646 (11.3)	3006 (18.1)	
Europe	3874 (67.8)	10239 (61.6)	
Latin America	423 (7.4)	1133 (6.8)	
Asia	768 (13.4)	2231 (13.4)	
Cardiovascular risk factors, %			
Hypertension	4191 (73.4)	13405 (80.7)	< 0.001
Diabetes mellitus	1699 (29.7)	6163 (37.1)	< 0.001
Current cigarette use	1532 (26.8)	4631 (27.9)	0.13
Time from most recent MI to randomization, median (IQR), years	0.4 (0.2-0.6)	4.9 (2.7-9.8)	< 0.001
History of stroke	265 (4.6)	1374 (8.3)	< 0.001
History of peripheral artery disease	266 (4.7)	1542 (9.3)	< 0.001
≥ 2 Prior myocardial infarctions	1461 (25.6)	3820 (23.0)	< 0.001
Residual multivessel CAD*	1484 (26.0)	4125 (24.9)	0.085
Prior coronary artery bypass graft	830 (14.6)	3954 (23.9)	< 0.001
Prior percutaneous coronary intervention	4290 (75.2)	10601 (63.9)	< 0.001
Statin use, %			< 0.001
High intensity	4415 (77.3)	11506 (69.3)	
Moderate intensity	1283 (22.5)	5066 (30.5)	
Ezetimibe, %	186 (3.3)	1051 (6.3)	< 0.001
LDL-C, median (IQR), mg/dL	90 (79-105)	93 (80-110)	< 0.001
HDL-C, median (IQR), mg/dL	43 (36-51)	44 (37-52)	< 0.001
hsCRP, median (IQR), mg/L	1.8 (0.9-3.7)	1.6 (0.8-3.4)	< 0.001
eGFR < 60 mL/min/1.73m²	845 (14.8)	3157 (19.0)	< 0.001

CABG, coronary artery bypass graft; CAD, coronary artery disease; eGFR, estimated glomerular filtration; hsCRP, high-sensitive C-reactive protein; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SD, standard deviation.
* Residual CAD was defined as ≥40% stenosis in ≥ 2 major vessels.

eTable 2. Achievement of recommended LDL-C targets at 4 weeks in patients with recent MI (≤12 months) vs remote MI (>12 months)

LDL-C at 4 weeks	Recent (≤12 months)			Remote (>12 months)		
	Evolocumab N=2690	Placebo N=2764	P-Value	Evolocumab N=8047	Placebo N=7990	P-value
LDL-C Targets						
LDL-C < 70 mg/dL, n (%)	2467 (91.7)	502 (18.2)	<0.001	7271 (90.4)	1361 (17.0)	<0.001
LDL-C < 55 mg/dL, n (%)	2254 (83.8)	124 (4.5)	<0.001	6700 (83.3)	305 (3.8)	<0.001
LDL-C < 40 mg/dL, n (%)	1717 (63.8)	9 (0.3)	<0.001	5081 (63.1)	26 (0.3)	<0.001
Abbreviations: LDL-C, low density lipoprotein-cholesterol						

eTable 3. Efficacy of evolocumab in patients with recent MI (≤12 months) vs remote MI (>12 months)

Outcomes	Recent (≤12 months)			Remote (>12 months)			P-int
	Evolocumab N Event (Kaplan-Meier Rate %)	Placebo N Event (Kaplan-Meier Rate %)	HR (95% CI)	Evolocumab N Event (Kaplan-Meier Rate %)	Placebo N Event (Kaplan-Meier Rate %)	HR (95% CI)	
Primary Endpoint							
Cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization	323 (13.5%)	408 (17.2%)	0.81 (0.70-0.93) P=0.004	851 (13.3%)	921 (14.4%)	0.92 (0.84-1.01) P=0.075	0.13
Key Secondary Endpoint							
Cardiovascular death, myocardial infarction, stroke	182 (7.7%)	248 (10.9%)	0.75 (0.62-0.91) P=0.003	502 (8.2%)	584 (9.5%)	0.85 (0.76-0.96) P=0.009	0.24
Additional Secondary Endpoints							
Cardiovascular death or myocardial infarction	164 (7.0%)	222 (9.6%)	0.75 (0.61-0.92) P=0.006	419 (6.7%)	481 (8.0%)	0.87 (0.76-0.99) P=0.032	0.24
Cardiovascular death	50 (2.3%)	52 (2.5%)	1.00 (0.68-1.47) P=0.99	156 (2.5%)	136 (2.2%)	1.15 (0.91-1.44) P=0.24	0.53
Myocardial infarction	127 (5.2%)	191 (8.0%)	0.67 (0.54-0.84) P< 0.001	296 (4.8%)	379 (6.4%)	0.78 (0.67-0.91) P=0.001	0.30
Stroke	30 (1.3%)	38 (1.9%)	0.81 (0.50-1.31) P=0.39	110 (2.0%)	137 (2.2%)	0.80 (0.62-1.03) P=0.081	0.94
Coronary revascularization	206 (8.8%)	283 (12.1%)	0.74 (0.62-0.89) P=0.001	489 (7.5%)	577 (9.1%)	0.84 (0.75-0.95) P=0.006	0.23

HRs and 95% confidence intervals (CI) for the effect of evolocumab versus placebo in recent vs. remote MI patients were generated with a Cox proportional hazards model with stratification factors of final screening LDL cholesterol and region as covariates.

eTable 4. Efficacy of evolocumab on the primary and key secondary end points by key subgroups

Primary endpoint (CV death, MI, stroke, hospitalization for unstable angina and coronary revascularization)				
	Recent MI (≤12 months)		Remote MI (> 12 months)	
Subgroups	HR (95% CI)	P-int	HR (95% CI)	P-int
Baseline high-intensity statin	0.78 (0.66-0.93)	0.46	0.94 (0.85-1.05)	0.36
No baseline high-intensity statin	0.88 (0.66-1.18)		0.85 (0.71-1.02)	
Baseline LDL-C <70 mg/dL	0.92 (0.53-1.62)	0.70	0.78 (0.54-1.13)	0.37
Baseline LDL-C ≥70 mg/dL	0.80 (0.69-0.93)		0.93 (0.84-1.02)	
Key secondary endpoint (CV death, MI or stroke)				
	Recent MI (≤12 months)		Remote MI (> 12 months)	
	HR (95% CI)	P-int	HR (95% CI)	P-int
Baseline high-intensity statin	0.76 (0.61-0.95)	0.89	0.87 (0.75-1.00)	0.67
No baseline high-intensity statin	0.72 (0.49-1.05)		0.82 (0.65-1.03)	
Baseline LDL-C <70 mg/dL	0.77 (0.34-1.75)	0.92	0.68 (0.43-1.07)	0.29
Baseline LDL-C ≥70 mg/dL	0.75 (0.62-0.91)		0.87 (0.77-0.98)	
Abbreviations: CI, confidence intervals; CV, cardiovascular; HR, hazard ratio; LDL-C, low-density lipoprotein-cholesterol; MI, myocardial infarction.				